Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advancements review discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide avail... https://samuelm478hxj4.wikipresses.com/user